Previous Article | Next Article 
Journal of Clinical Microbiology, August 2000, p. 2998-3003, Vol. 38, No. 8
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Genetic and Serologic Evaluation of Capsule
Production by Bovine Mammary Isolates of Staphylococcus
aureus and Other Staphylococcus spp. from Europe and
the United States
T.
Tollersrud,1,*
K.
Kenny,2
A. J.
Reitz Jr.,3 and
J. C.
Lee3
Section of Immunoprophylaxis, National
Veterinary Institute, Oslo, Norway1; Key
Laboratories Ltd., Dublin, Ireland2; and
Channing Laboratory, Department of Medicine, Brigham and
Women's Hospital, Harvard Medical School, Boston,
Massachusetts3
Received 16 December 1999/Returned for modification 29 March
2000/Accepted 29 May 2000
 |
ABSTRACT |
Bovine mastitis caused by Staphylococcus aureus is
responsible for major economic losses to the dairy industry, and
more-effective therapeutic or preventive approaches are sorely needed.
The predominance of staphylococcal capsular polysaccharide types 5 and
8 among human isolates from many sources is well documented, but there seems to be a greater variation in the distribution of capsular serotypes among isolates from cows. A total of 636 isolates of S. aureus from cases of bovine mastitis in Sweden, Denmark, Finland, Iceland, Ireland, and the United States were investigated for production of capsular polysaccharide types 5 and 8. Approximately half
of all the European isolates tested were of serotype 8, although variation among countries and among isolates of clinical and
subclinical origin was observed. Sweden had the highest frequency
(87%) of serotypeable isolates, and Finland had the lowest (48%).
Capsule types 5 and 8 accounted for only 42% of the U.S. isolates
tested. A few isolates showed weak reactivity with CP5 antiserum in a colony blot assay, and an enzyme-linked immunosorbent assay inhibition method confirmed that the levels of capsule produced by these strains
were <10% of those produced by control strains. Fifty isolates that
failed to react with capsular antisera all possessed the genes for
production of capsular polysaccharide type 5 or 8. These results
underscore the variability in capsule production by bovine isolates of
S. aureus from different geographic regions. This
information is important for the rational design of a capsule-based vaccine to prevent S. aureus bovine mastitis.
 |
INTRODUCTION |
Mastitis is the most significant
cause of economic loss to the dairy industry. Although several
bacterial pathogens can cause mastitis, Staphylococcus
aureus is a prime etiologic agent in most parts of the world.
S. aureus strains produce capsular polysaccharide (CP) in
vivo or under defined culture conditions (20, 36). Encapsulated S. aureus strains are more resistant to
phagocytic uptake than are nonencapsulated strains, and antibodies to
CP opsonize encapsulated strains for phagocytic killing (15,
38). In rodent models of staphylococcal infection (8,
19), capsular antibodies protected animals against death,
bacteremia, endocarditis, and metastasis to the spleen, liver, and kidneys.
Eleven CP serotypes have been proposed on the basis of agglutinating
reactivity with adsorbed rabbit antiserum and precipitation in double
immunodiffusion (16, 34). Whereas there is general agreement
that CP5 and CP8 are the predominant serotypes in human S. aureus infections, evaluation of capsule production among S. aureus strains from ruminants shows varying results. In France, 69% of 212 isolates recovered from cows' milk were of serotype 5 (51%) or 8 (18%) (31). In contrast, only 17% of 18 isolates from bovine mastitis in Israel produced either the serotype 5 or the serotype 8 capsule (34). A recent report
(35) indicated that only 14% of 195 bovine isolates from
Argentina reacted with antibodies to CP5 or CP8. Guidry et al.
(10, 11) evaluated the prevalence of serotype 5 and 8 capsules among S. aureus strains from mastitic cows in the
United States and in four European countries. They showed that 41 and
70% of the U.S. and European isolates, respectively, were typeable
with antibodies to CP5 or CP8.
Strains of S. aureus that do not react with antibodies to
CP5 or CP8 are referred to as nontypeable (NT). These NT strains also
fail to react with specific antibodies to serotype 1 or 2 CP (14,
18). Whether NT strains lack a capsule or produce a heterologous
capsule type is unknown, since specific antibodies to proposed
serotypes 3, 6, 7, 9, 10, and 11 are not available. Antibodies to
serotype 5 react with the only serotype 4 strain that has been
identified (14). Moreover, only CPs from serotypes 1, 2, 5, and 8 have been purified and chemically characterized (9, 22, 26,
27). The question of whether NT strains carry genes involved in
capsule expression has only recently been addressed (35).
The genes involved in serotype 5 and 8 capsule biosynthesis are
chromosomal and allelic (33). Each gene cluster contains 16 open reading frames (ORFs), designated cap5A through
cap5P for type 5 CP and cap8A through
cap8P for type 8 CP. The predicted amino acid sequences of
12 of the 16 ORFs of the cap5 and cap8 gene
clusters are almost identical. However, four ORFs located in the
central region (cap5H through cap5K or
cap8H through cap8K) bear little homology to each
other and are type specific.
The aim of this study was to evaluate the prevalence of serotypes 5 and
8 among bovine mammary isolates of S. aureus from four
Nordic countries, Ireland, and the United States. Staphylococcal CPs
may play a role in the pathogenesis of bovine mastitis because of their
virulence-enhancing, antiphagocytic properties. Information concerning the geographical distribution of capsular serotypes is
important for the rational design and use of vaccines against S. aureus mastitis based on capsular antigens. We also sought to
investigate the genotype of NT S. aureus strains by
hybridization studies and thus to determine whether they carry genes
similar to those that encode the enzymes for the synthesis and
polymerization of CP5 and CP8.
 |
MATERIALS AND METHODS |
Bacteria.
Six hundred thirty-six isolates of S. aureus were obtained from the milk of cows with clinical or
subclinical mastitis. The milk samples were collected from dairy herds
in the United States, Sweden, Denmark, Finland, Iceland, and Ireland.
Most of the isolates were from separate dairy herds within each region.
The S. aureus isolates were initially selected on the basis
of colony appearance and a positive tube coagulase test and their
identity was verified by API-Staph (bioMérieux Vitek, Inc.,
Hazelwood, Mo.) or Rapidec-Staph (bioMérieux, Marcy
l'Etoile, France) or by amplification of a 108-bp S. aureus-specific DNA fragment by PCR (24).
Coagulase-negative staphylococci isolated from clinical cases of bovine
mastitis were identified to the species level by standard biochemical
methods, API- and Rapidec-Staph, and by their failure to yield an
S. aureus-specific amplicon by PCR. The bacteria were stored
at
70°C in 10% skim milk or heart infusion broth (Difco
Laboratories, Detroit, Mich.) with 15% glycerol.
On the basis of clinical data, the isolates from Denmark, Finland,
Iceland, Ireland, and Sweden were designated as originating from
clinical or subclinical mastitis as defined by the National Mastitis
Council (3). In brief, subclinical mastitis was defined as a
form of the disease with no detectable change in the udder and no
grossly observable abnormalities in the milk. Acute or clinical
mastitis was defined as a condition of sudden onset with grossly
abnormal milk and redness, swelling, and pain in the udder, with or
without systemic symptoms.
Antibodies.
Polyclonal antisera were raised in rabbits to
heat- or formalin-killed suspensions of prototype S. aureus
strains Reynolds (serotype 5), Becker (serotype 8), and PS80 (serotype
8). Sera were adsorbed with S. aureus Wood 46 and
trypsinized cells of acapsular mutants JL243 (2) and JL252
(5) to remove antibodies to noncapsular cell wall
determinants. CP5-specific monoclonal antibody S831 and CP8-specific
monoclonal antibody S828 were kindly provided by H. K. Hochkeppel.
Capsule serotyping.
Our serotyping experiments were
performed only with antibodies to CP5 and CP8, since strains expressing
CP1 and CP2 possess mucoid colony morphology and are extremely rare
(4, 34). Colony immunoblots were performed as described
previously (18) with CP5- or CP8-specific antibodies.
Reactivity of the bovine isolates was evaluated by comparison with that
of the control strains (types 1, 2, 5, and 8 and NT) included on each
filter. Each isolate was tested at least twice. Reactions scored as 2+ to 4+ were recorded as positive, and isolates that reacted weakly (0 to
1+) were recorded as NT with the given antisera. Isolates consistently
giving weak reactions with antibodies to CP5 or CP8 were further
evaluated by immunodiffusion and/or enzyme-linked immunosorbent assay
(ELISA) inhibition.
For preparation of crude capsular extracts,
S. aureus was
cultivated for 24 h at 37°C on either tryptic soy agar (Difco
Laboratories)
or Columbia agar (Difco Laboratories) supplemented with
2% NaCl.
The colonies from one 9-cm-diameter plate were harvested in 1
ml of 10 mM phosphate-buffered saline (0.15 M NaCl, pH 7.2), and
the
bacterial suspension was autoclaved for 1 h at 121°C. The
bacteria were sedimented by centrifugation, and the supernatant
was
passed through a filter (pore size, 0.45 µm) and stored at

20°C.
The quality of the capsular extract was verified by its
reactivity with
teichoic acid antiserum. Reactivity of the capsular
extracts with
antisera to CP5 and CP8 was evaluated by double
immunodiffusion.
An ELISA inhibition method was used to quantitate CP5 produced by 16 bovine
S. aureus isolates from four countries. This assay,
described previously (
2,
20), is based on the ability of
purified CP5 or whole bacteria (trypsinized to remove protein
A) to
adsorb capsular antibodies from immune
sera.
DNA hybridization experiments.
To determine whether NT
S. aureus isolates carry the genes involved in CP5 or CP8
expression, we performed DNA hybridization studies. Genomic DNA was
extracted from 50 NT bovine isolates of S. aureus and 14 isolates of coagulase-negative Staphylococcus spp. from
cases of bovine mastitis. Strains Newman (serotype 5) and Becker
(serotype 8), in addition to bovine isolates of serotypes 5 and 8, were
included in the hybridization studies as positive controls. DNA from
each isolate was digested with HindIII (Life Technologies, Gaithersburg, Md.) and electrophoresed in a 0.8% agarose
gel. The DNA was transferred to a nylon membrane (Gene Screen; NEN
Research Products, Boston, Mass.) and probed sequentially with cloned
DNA fragments (cap5ABCD, cap5IJK,
cap8HIJK, or cap5MNOP) that were enzyme labeled
with AlkPhos Direct (Amersham Life Science, Inc., Arlington Heights,
Ill.). Membrane hybridization and washing steps were performed as
directed by the manufacturer at 60°C. Membrane stripping and
autoradiography were carried out in accordance with the manufacturer's recommendations.
 |
RESULTS |
The results of capsular serotyping of 274 bovine mastitis isolates
of S. aureus from Europe are shown in Table
1. Marked differences in the distribution
of isolates expressing CP5 or CP8 among the various countries were
observed. When European isolates from all cases of mastitis (clinical
and subclinical) were considered, the majority of isolates from
Denmark, Sweden, and Ireland were of serotype 8. Isolates from Iceland
showed an equal distribution of serotype 5, serotype 8, and NT
isolates, whereas in Finland half of the isolates tested were NT. The
typeable Finnish isolates were equally distributed between serotypes 5 and 8. Among the Danish, Swedish, and Finnish S. aureus
isolates, there was no significant difference between the serotype
distributions of clinical and subclinical staphylococcal isolates
(Table 1). For Icelandic and Irish isolates, a higher proportion of
clinical than of subclinical isolates was of serotype 8 (P < 0.05 by chi-square analysis).
Serotyping of the U.S. isolates revealed that only 42% of 362 isolates
from seven different states were typeable with the available antisera
(Table 2). Serotype 8 strains were
recovered almost twice as often as serotype 5 strains, but the majority (58%) of U.S. isolates were NT. As shown in Table 2, there was little
difference in serotype distribution among strains from cows in
different states. Data on the clinical status of infection were not
obtained for isolates from the United States.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Results of capsular serotyping of isolates of S. aureus from cases of bovine mastitis in the United States
|
|
Quantitation of CP5 production.
We identified a subset of
S. aureus isolates that consistently reacted weakly with CP5
antiserum in the colony immunoblot assay. Production of cell
surface-associated CP5 was quantitated for 12 of these weakly reactive
isolates and for five control strains (one of human origin, four of
bovine origin) that reacted strongly (4+ reactions) in the colony
immunoblot assay with CP5-specific antiserum. A positive control strain
was included in each experiment, since there is day-to-day variability
in capsule expression by control strain Reynolds. As shown in Table
3, a positive correlation existed between
the strength of the reaction in the immunoblot and the quantitative
ELISA results. Three S. aureus isolates that reacted
strongly in the colony immunoblot assays showed >50% of the capsule
expression of strain Reynolds, whereas the weakly reactive isolates
showed <10% of the cell surface-associated CP5 expression of the
positive control strain.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Correlation between reactivity in the immunoblot and
quantitative CP5 expression measured by ELISA inhibition
|
|
Hybridization of genomic DNA from NT S. aureus with the
cap5 and cap8 genes.
To determine whether
NT S. aureus strains carry the genes involved in CP5 or CP8
expression, DNA hybridization studies were performed. Southern blots of
genomic DNA digests from each isolate were probed consecutively with
cloned DNA fragments representing either the regions of the capsule
gene clusters that are shared by type 5 and 8 strains or the regions
that are unique to the cap5 or cap8 gene cluster.
The results, shown in Table 4, indicate that 48 of the 50 NT isolates tested carry the cap5 genes,
although they did not express detectable levels of CP5. Only two of the NT isolates, one each from Sweden and Iceland, carried the
cap8 genes. The size of the hybridizing bands of the NT
strains did not differ from those of the control serotype 5 and 8 strains (not shown), a result suggesting that each NT isolate carries an intact capsule gene cluster. As expected, none of the DNA samples hybridized to both cap5- and cap8-specific
fragments, since the cap5 and cap8 loci are
allelic.
Hybridization of genomic DNAs from Staphylococcus spp.
with the cap5 and cap8 genes.
Poutrel et
al. (32) reported that 16 of 74 coagulase-negative
staphylococci of bovine origin reacted with monoclonal antibodies to
S. aureus CP5 or CP8. Thirteen of the 16 reactive strains
were S. haemolyticus isolates. To examine this phenomenon
further, 14 isolates of staphylococcal species other than S. aureus were tested for capsule production by serologic methods and
for the presence of the cap5 or cap8 genes by
Southern blot hybridization. The isolates tested, all of which were
recovered from bovine milk, included seven isolates of S. haemolyticus, three of S. intermedius, two of S. chromogenes, and one each of S. xylosus and S. simulans. Except for the S. haemolyticus isolates, none
of the isolates reacted with the capsular antibodies or carried genes
that hybridized with the capsule gene probes (Table
5). In contrast, all seven S. haemolyticus isolates reacted with both polyclonal and monoclonal antibodies specific for CP5. Under our standard conditions for hybridization (high stringency, 60°C), genomic DNA prepared from the
S. haemolyticus isolates did not hybridize to either a
cap5 or a cap8 gene probe. However, under
low-stringency (50°C) conditions, a mixture of cap5 probes
hybridized weakly to chromosomal DNAs from the S. haemolyticus isolates.
 |
DISCUSSION |
The results of this study underscore the considerable variability
that exists in the prevalence of serotype 5 and 8 capsules among bovine
mammary isolates of S. aureus from different countries. CP8
expression predominated among staphylococcal isolates from Denmark,
Sweden, and Ireland. In contrast, Poutrel et al. reported that serotype
5 strains accounted for half of 212 isolates from France while only
18% of the strains were of serotype 8 (31). Our data
indicate that 63% of 274 bovine mammary isolates of S. aureus tested from five European countries (Denmark, Sweden,
Finland, Iceland, and Ireland) expressed either serotype 5 or 8 CPs. At the other extreme are bovine mammary isolates from Argentina, of which
86% are NT (35). In the United Kingdom, Germany, and The
Netherlands, there appears to be an equal distribution of serotype 5, serotype 8, and NT isolates (11). We found that only 42% of
369 bovine isolates from the United States expressed CP5 or CP8,
consistent with results from a previous study (10).
Our data also suggest a correlation between capsule production and the
clinical severity of mastitis in Iceland and Ireland, where >90% of
isolates from cows with clinical mastitis were encapsulated. The
subclinical isolates from Iceland and Ireland were only 57 and 58%
positive, respectively, for capsule production. No such correlation was
found for isolates from three other countries (Denmark, Sweden, and
Finland), however. The clustering of typeable isolates among the
clinical mastitis strains may be influenced by the occurrence of local
clones of S. aureus that become widely disseminated within a
single region. With the use of ribotyping and phage typing, Aarestrup
et al. found regional clones of S. aureus isolates from
bovine mastitis distributed within the Nordic countries (1).
Unlike bovine isolates, S. aureus isolates cultured from
humans residing in diverse geographic regions show only subtle differences in the prevalence of capsule expression. Approximately 75%
of all human S. aureus isolates (both commensal and disease isolates) are positive for either CP5 or CP8 (4, 13, 34). This difference in capsule production between bovine and human isolates
probably reflects limited diversity among the bovine isolates within a
particular geographic region.
All 50 of the NT S. aureus isolates tested in this study
possessed the cap genes required for the synthesis of either
CP5 or CP8. The fact that 48 of the 50 NT isolates possessed
cap5 genes is noteworthy and merits further investigation.
It is possible that these NT isolates have point mutations in one or
more of the 16 genes involved in capsule expression, as has been shown for the NT strain S. aureus NCTC 8325-4 (6, 21,
39). This strain carries an intact copy of the cap5
gene cluster, but a mutation in cap5E renders it capsule
negative. Alternatively, these NT isolates may produce undetectable
levels of CP due to poor promoter activity or regulatory effects.
Although capsule production is known to be influenced by a number of
environmental factors, such as energy availability and source, oxygen
supply, and the amino acid content of the growth medium (12, 20,
36, 37), the genetic mechanisms regulating CP expression in
S. aureus are largely unknown.
We detected a subset of bovine S. aureus isolates that
expressed <10% of the cell surface-associated CP5 produced by
prototype strain Reynolds. These strains were only weakly reactive by
the colony immunoblot method. The expression of scant amounts of CP5 by
this subset may reflect a defect in the capsule gene cluster or
regulatory control mechanisms. Alternatively, production of CP by an
individual S. aureus isolate may vary under different laboratory growth conditions or during growth in the mammary gland. The
clinical significance of S. aureus CP production in the
pathogenesis of mastitis is unknown, and the biological significance of
scant CP production in this disease has not been evaluated. Strain
Reynolds was significantly more virulent in a mouse bacteremia model
than was either an acapsular mutant (JL243) or a mutant that expressed 9% of the wild-type level of CP5 (JL236). While both mutants were opsonized for phagocytic killing by nonimmune serum with complement activity, strain Reynolds resisted phagocytosis and required
capsule-specific antibodies and complement for opsonization
(38). In a murine model, septic arthritis was of
intermediate frequency and severity in mice inoculated with the
CP-deficient mutant JL236, as opposed to the parental strain or the
acapsular mutant (29).
Of particular interest in our study was the observation that all seven
of the S. haemolyticus strains tested showed serologic evidence of CP5 expression, but that genomic DNA prepared from these
seven isolates failed to hybridize to the cap5 genes under high-stringency conditions. Hybridization was observed under
low-stringency conditions to genomic, but not plasmid, DNA from these
strains, a result suggesting that S. haemolyticus does carry
cap genes with limited homology to those from S. aureus. Poutrel et al. showed that 13 of 19 S. haemolyticus isolates of bovine origin reacted with monoclonal
antibodies to CP5 (32). Nelles et al. (28) showed
that S. epidermidis clinical isolates did not react with
CP5- or CP8-specific monoclonal antibodies. Similar findings were
reported by Boutonnier et al. (7), who observed no reactions between capsule-specific monoclonal antibodies and members of 25 Staphylococcus species other than S. aureus,
including one strain of S. haemolyticus (ATCC
29970T). Moreover, of 678 blood culture isolates of
coagulase-negative staphylococcal species (primarily S. epidermidis), none reacted by ELISA with capsular antibodies.
It is plausible that NT bovine isolates of S. aureus make a
capsule unrelated to CP5 or CP8 that is not detected by our capsular antibodies or by hybridization with the cap gene
region-specific DNA probes. Several authors have described the
existence of other, less-defined capsular or surface antigens among
bovine mastitis isolates of S. aureus (23, 30,
40). Guidry et al. (11) reported that a new antigen
called 336 was present on bovine isolates of S. aureus that
did not produce CP5 or CP8. However, the authors did not distinguish
this antigen from teichoic acid (17). A recent study
revealed that 29 (35%) of 82 NT S. aureus isolates from
cases of bovine mastitis in the United States were reactive with
antibodies to a newly described staphylococcal surface polysaccharide composed of poly-N-succinylglucosamine (PNSG)
(25). The relationship of PNSG and CP to previously
described bovine staphylococcal surface antigens is largely unknown.
PNSG expression was independent of CP5 or CP8 expression; i.e., it was
produced by NT strains, as well as by strains positive for CP5 or CP8.
The results of capsule serotyping studies of isolates from different
countries are important for the rational design of mastitis vaccines
containing staphylococcal capsular antigens. If improved vaccines
against bovine mastitis are to be generated, more studies must
elucidate the role of these polysaccharides in the pathogenesis of
bovine mastitis. The creation and use of isogenic, capsule-negative S. aureus mutants of bovine origin in infection models of
mastitis would add to the current knowledge. Ongoing studies will
determine whether immunization with CP5 or CP8 will be protective
against experimental bovine mastitis.
 |
ACKNOWLEDGMENTS |
We thank Torsteinn Olafsson (Iceland), Anna Huda (Denmark),
Lolita Nilsson (Sweden), Tuula Honkanen-Buzalski (Finland), and Ross
Fitzgerald (Ireland) for providing S. aureus isolates from Europe. We are grateful for the coagulase-negative staphylococci supplied by Steinar Waage and Tormod Mørk. We thank the following individuals for providing bovine isolates from the United States: James
Cullor, Larry Fox, R. J. Harmon, Steve Nickerson, J. W. Pankey, Richard A. Wilson, and William E. Owens. We gratefully acknowledge the gift of monoclonal antibodies from H. K. Hochkeppel. We thank Jessica Lam for her assistance in the DNA
hybridization studies.
This work was supported by VESO AS and National Institutes of Health
grant AI29040 (to Jean Lee).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: National
Veterinary Institute, P.B. 8156, 0033 Oslo Dep., Norway. Phone: 47 2296 4648. Fax: 47 2246 8890. E-mail:
tore.tollersrud{at}vetinst.no.
 |
REFERENCES |
| 1.
|
Aarestrup, F. M.,
H. C. Wegener,
N. E. Jensen,
O. Jonsson,
V. Myllys,
B. M. Thorberg,
S. Waage, and V. T. Rosdahl.
1997.
A study of phage- and ribotype patterns of Staphylococcus aureus isolated from bovine mastitis in the Nordic countries.
Acta Vet. Scand.
38:243-252[Medline].
|
| 2.
|
Albus, A.,
R. D. Arbeit, and J. C. Lee.
1991.
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.
Infect. Immun.
59:1008-1014[Abstract/Free Full Text].
|
| 3.
|
Anonymous.
1996.
Mastitis can take on several different forms.
Natl. Mastitis Counc. Newsl.
19:1.
|
| 4.
|
Arbeit, R. D.,
W. W. Karakawa,
W. F. Vann, and J. B. Robbins.
1984.
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus.
Diagn. Microbiol. Infect. Dis.
2:85-91[CrossRef][Medline].
|
| 5.
|
Baddour, L. M.,
C. Lowrance,
A. Albus,
J. H. Lowrance,
S. K. Anderson, and J. C. Lee.
1992.
Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis.
J. Infect. Dis.
165:749-753[Medline].
|
| 6.
|
Bhasin, N.,
A. Albus,
F. Michon,
P. J. Livolsi,
J. S. Park, and J. C. Lee.
1998.
Identification of a gene essential for O-acetylation of the Staphylococcus aureus type 5 capsular polysaccharide.
Mol. Microbiol.
27:9-21[CrossRef][Medline].
|
| 7.
|
Boutonnier, A.,
F. Nato,
A. Bouvet,
L. Lebrun,
A. Audurier,
J. C. Mazie, and J. M. Fournier.
1989.
Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus.
J. Clin. Microbiol.
27:989-993[Abstract/Free Full Text].
|
| 8.
|
Fattom, A.,
J. Sarwar,
A. Ortiz, and R. Naso.
1996.
A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
Infect. Immun.
64:1659-1665[Abstract].
|
| 9.
|
Fournier, J. M.,
W. F. Vann, and W. W. Karakawa.
1984.
Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide.
Infect. Immun.
45:87-93[Abstract/Free Full Text].
|
| 10.
|
Guidry, A. J.,
A. Fattom,
A. Patel, and C. O'Brien.
1997.
Prevalence of capsular serotypes among Staphylococcus aureus isolates from cows with mastitis in the United States.
Vet. Microbiol.
59:53-58[CrossRef][Medline].
|
| 11.
|
Guidry, A. J.,
A. Fattom,
A. Patel,
C. O'Brien,
S. Shepherd, and J. Lohuis.
1998.
Serotyping scheme for Staphylococcus aureus isolated from cows with mastitis.
Am. J. Vet. Res.
59:1537-1539[Medline].
|
| 12.
|
Herbert, S.,
D. Worlitzsch,
B. Dassy,
A. Boutonnier,
J. M. Fournier,
G. Bellon,
A. Dalhoff, and G. Doring.
1997.
Regulation of Staphylococcus aureus capsular polysaccharide type 5: CO2 inhibition in vitro and in vivo.
J. Infect. Dis.
176:431-438[Medline].
|
| 13.
|
Hochkeppel, H. K.,
D. G. Braun,
W. Vischer,
A. Imm,
S. Sutter,
U. Staeubli,
R. Guggenheim,
E. L. Kaplan,
A. Boutonnier, and J. M. Fournier.
1987.
Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8.
J. Clin. Microbiol.
25:526-530[Abstract/Free Full Text].
|
| 14.
|
Karakawa, W. W.,
J. M. Fournier,
W. F. Vann,
R. D. Arbeit,
R. Schneerson, and J. B. Robbins.
1985.
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus.
J. Clin. Microbiol.
22:445-447[Abstract/Free Full Text].
|
| 15.
|
Karakawa, W. W.,
A. Sutton,
R. Schneerson,
A. Karpas, and W. F. Vann.
1988.
Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes.
Infect. Immun.
56:1090-1095[Abstract/Free Full Text].
|
| 16.
|
Karakawa, W. W., and W. F. Vann.
1982.
Capsular polysaccharides of Staphylococcus aureus.
Semin. Infect. Dis.
4:285-293.
|
| 17.
|
Kenny, K., and T. Tollersrud.
1999.
Questions uniqueness of surface polysaccharide.
Am. J. Vet. Res.
60:530[Medline].
|
| 18.
|
Lee, J. C.,
M. J. Liu,
J. Parsonnet, and R. D. Arbeit.
1990.
Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus.
J. Clin. Microbiol.
28:2612-2615[Abstract/Free Full Text].
|
| 19.
|
Lee, J. C.,
J. S. Park,
S. E. Shepherd,
V. Carey, and A. Fattom.
1997.
Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats.
Infect. Immun.
65:4146-4151[Abstract].
|
| 20.
|
Lee, J. C.,
S. Takeda,
P. J. Livolsi, and L. C. Paoletti.
1993.
Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus.
Infect. Immun.
61:1853-1858[Abstract/Free Full Text].
|
| 21.
|
Lee, J. C.,
S. Xu,
A. Albus, and P. J. Livolsi.
1994.
Genetic analysis of type 5 capsular polysaccharide expression by Staphylococcus aureus.
J. Bacteriol.
176:4883-4889[Abstract/Free Full Text].
|
| 22.
|
Liau, D. F., and J. H. Hash.
1977.
Structural analysis of the surface polysaccharide of Staphylococcus aureus M.
J. Bacteriol.
131:194-200[Abstract/Free Full Text].
|
| 23.
|
Mamo, W., and G. Froman.
1994.
In vivo-like antigenic surface properties of Staphylococcus aureus from bovine mastitis induced upon growth in milk whey.
Microbiol. Immunol.
38:801-804[Medline].
|
| 24.
|
Martineau, F.,
F. J. Picard,
P. H. Roy,
M. Ouellette, and M. G. Bergeron.
1998.
Species-specific and ubiquitous-DNA-based assays for rapid identification of Staphylococcus aureus.
J. Clin. Microbiol.
36:618-623[Abstract/Free Full Text].
|
| 25.
|
McKenney, D.,
K. L. Pouliot,
Y. Wang,
V. Murthy,
M. Ulrich,
G. Doring,
J. C. Lee,
D. A. Goldmann, and G. B. Pier.
1999.
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
Science
284:1523-1527[Abstract/Free Full Text].
|
| 26.
|
Moreau, M.,
J. C. Richards,
J. M. Fournier,
R. A. Byrd,
W. W. Karakawa, and W. F. Vann.
1990.
Structure of the type 5 capsular polysaccharide of Staphylococcus aureus.
Carbohydr. Res.
201:285-297[CrossRef][Medline].
|
| 27.
|
Murthy, S. V.,
M. A. Melly,
T. M. Harris,
C. G. Hellerqvist, and J. H. Hash.
1983.
The repeating sequence of the capsular polysaccharide of Staphylococcus aureus M.
Carbohydr. Res.
117:113-123[CrossRef][Medline].
|
| 28.
|
Nelles, M. J.,
C. A. Niswander,
W. W. Karakawa,
W. F. Vann, and R. D. Arbeit.
1985.
Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide.
Infect. Immun.
49:14-18[Abstract/Free Full Text].
|
| 29.
|
Nilsson, I. M.,
J. C. Lee,
T. Bremell,
C. Ryden, and A. Tarkowski.
1997.
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis.
Infect. Immun.
65:4216-4221[Abstract].
|
| 30.
|
Opdebeeck, J. P.,
A. J. Frost,
D. O'Boyle, and N. L. Norcross.
1987.
The expression of capsule in serum-soft agar by Staphylococcus aureus isolated from bovine mastitis.
Vet. Microbiol.
13:225-234[CrossRef][Medline].
|
| 31.
|
Poutrel, B.,
A. Boutonnier,
L. Sutra, and J. M. Fournier.
1988.
Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk.
J. Clin. Microbiol.
26:38-40[Abstract/Free Full Text].
|
| 32.
|
Poutrel, B.,
C. Mendolia, and J. M. Fournier.
1990.
Reactivity of coagulase-negative staphylococci isolated from cow and goat milk with monoclonal antibodies to Staphylococcus aureus capsular polysaccharide types 5 and 8.
J. Clin. Microbiol.
28:358-360[Abstract/Free Full Text].
|
| 33.
|
Sau, S.,
N. Bhasin,
E. R. Wann,
J. C. Lee,
T. J. Foster, and C. Y. Lee.
1997.
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes.
Microbiology
143:2395-2405[Abstract/Free Full Text].
|
| 34.
|
Sompolinsky, D.,
Z. Samra,
W. W. Karakawa,
W. F. Vann,
R. Schneerson, and Z. Malik.
1985.
Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types.
J. Clin. Microbiol.
22:828-834[Abstract/Free Full Text].
|
| 35.
|
Sordelli, D. O.,
F. R. Buzzola,
M. I. Gomez,
L. Steele-Moore,
D. Berg,
E. Gentilini,
M. Catalano,
A. J. Reitz,
T. Tollersrud,
G. Denamiel,
P. Jeric, and J. C. Lee.
2000.
Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiological analyses.
J. Clin. Microbiol.
38:846-850[Abstract/Free Full Text].
|
| 36.
|
Stringfellow, W. T.,
B. Dassy,
M. Lieb, and J. M. Fournier.
1991.
Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media.
Appl. Environ. Microbiol.
57:618-621[Abstract/Free Full Text].
|
| 37.
|
Sutra, L.,
P. Rainard, and B. Poutrel.
1990.
Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk.
J. Clin. Microbiol.
28:2253-2258[Abstract/Free Full Text].
|
| 38.
|
Thakker, M.,
J. S. Park,
V. Carey, and J. C. Lee.
1998.
Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.
Infect. Immun.
66:5183-5189[Abstract/Free Full Text].
|
| 39.
|
Wann, E. R.,
B. Dassy,
J. M. Fournier, and T. J. Foster.
1999.
Genetic analysis of the cap5 locus of Staphylococcus aureus.
FEMS Microbiol. Lett.
170:97-103[CrossRef][Medline].
|
| 40.
|
Watson, D. L., and N. A. Watson.
1989.
Expression of a pseudocapsule by Staphylococcus aureus: influence of cultural conditions and relevance to mastitis.
Res. Vet. Sci.
47:152-157[Medline].
|
Journal of Clinical Microbiology, August 2000, p. 2998-3003, Vol. 38, No. 8
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Flahaut, S., Vinogradov, E., Kelley, K. A., Brennan, S., Hiramatsu, K., Lee, J. C.
(2008). Structural and Biological Characterization of a Capsular Polysaccharide Produced by Staphylococcus haemolyticus. J. Bacteriol.
190: 1649-1657
[Abstract]
[Full Text]
-
Tuchscherr, L. P. N., Gomez, M. I., Buzzola, F. R., Calvinho, L. F., Lee, J. C., Sordelli, D. O.
(2007). Characterization of a New Variant of IS257 That Has Displaced the Capsule Genes within Bovine Isolates of Staphylococcus aureus. Infect. Immun.
75: 5483-5488
[Abstract]
[Full Text]
-
Buzzola, F. R., Alvarez, L. P., Tuchscherr, L. P. N., Barbagelata, M. S., Lattar, S. M., Calvinho, L., Sordelli, D. O.
(2007). Differential Abilities of Capsulated and Noncapsulated Staphylococcus aureus Isolates from Diverse agr Groups To Invade Mammary Epithelial Cells. Infect. Immun.
75: 886-891
[Abstract]
[Full Text]
-
Tuchscherr, L. P. N., Buzzola, F. R., Alvarez, L. P., Caccuri, R. L., Lee, J. C., Sordelli, D. O.
(2005). Capsule-Negative Staphylococcus aureus Induces Chronic Experimental Mastitis in Mice. Infect. Immun.
73: 7932-7937
[Abstract]
[Full Text]
-
Rabello, R. F., Souza, C. R. V. M., Duarte, R. S., Lopes, R. M. M., Teixeira, L. M., Castro, A. C. D.
(2005). Characterization of Staphylococcus aureus Isolates Recovered from Bovine Mastitis in Rio de Janeiro, Brazil. J DAIRY SCI
88: 3211-3219
[Abstract]
[Full Text]
-
Kampen, A. H., Tollersrud, T., Lund, A.
(2005). Staphylococcus aureus Capsular Polysaccharide Types 5 and 8 Reduce Killing by Bovine Neutrophils In Vitro. Infect. Immun.
73: 1578-1583
[Abstract]
[Full Text]
-
O'Riordan, K., Lee, J. C.
(2004). Staphylococcus aureus Capsular Polysaccharides. Clin. Microbiol. Rev.
17: 218-234
[Abstract]
[Full Text]
-
Ma, J., Cocchiaro, J., Lee, J. C.
(2004). Evaluation of Serotypes of Staphylococcus aureus Strains Used in the Production of a Bovine Mastitis Bacterin. J DAIRY SCI
87: 178-182
[Abstract]
[Full Text]
-
Boerlin, P., Kuhnert, P., Hussy, D., Schaellibaum, M.
(2003). Methods for Identification of Staphylococcus aureus Isolates in Cases of Bovine Mastitis. J. Clin. Microbiol.
41: 767-771
[Abstract]
[Full Text]